| Market Capitalization (Millions $) |
2,355 |
| Shares
Outstanding (Millions) |
157 |
| Employees |
34 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-51 |
| Cash Flow (TTM) (Millions $) |
-98 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company that primarily focuses on developing and commercializing drugs for neurological disorders. The company was founded in 2011 and is headquartered in New Haven, Connecticut.
The company's lead product candidate is nalbuphine ER, which is a novel extended-release formulation of nalbuphine, an opioid-based drug. It is under development for the treatment of several severe neurological conditions, including pruritus (severe itching) associated with conditions such as chronic liver disease and uremic (kidney-related) pruritus.
Trevi's pipeline also includes other drug candidates. One of them is TRV027, which is a novel human angiotensin type II receptor (AT2R) agonist. It is under development for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), which are severe and often fatal conditions that affect the lungs.
The company's scientific approach is based on in-depth understanding of the underlying pathophysiology of the diseases it targets. It uses innovative drug delivery technologies to extend the half-life of its drug candidates and optimize their therapeutic potential.
Trevi has partnerships with several leading institutions in the field of neurological research, including the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, and the Michael J. Fox Foundation for Parkinson's Research. The company is also engaged in collaborations with academic institutions and other pharmaceutical companies to advance the understanding of neurological diseases and develop innovative therapies.
In addition, Trevi has a strong management team with extensive experience in drug development and commercialization. Its executives have a track record of successfully bringing innovative therapies to market.
Overall, Trevi Therapeutics Inc. is a promising biopharmaceutical company that is dedicated to developing innovative therapies for severe neurological disorders. With its strong scientific approach, innovative drug delivery technologies, and experienced management team, it has the potential to create significant value for patients and investors alike.
Company Address: 195 Church Street New Haven 6510 CT
Company Phone Number: 304-2499 Stock Exchange / Ticker: NASDAQ TRVI
|
